^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hodgkin Lymphoma

    Related cancers:
    1d
    Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=16, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=18, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Epkinly (epcoritamab-bysp) • Truxima (rituximab-abbs) • Mabtas (rituximab biosimilar)
    1d
    NCI-2020-09704: Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Mayo Clinic | Trial completion date: Aug 2027 --> Jun 2026
    Trial completion date
    |
    Xpovio (selinexor)
    2d
    Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial (clinicaltrials.gov)
    P=N/A, N=24, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting | Trial completion date: May 2026 --> Dec 2026 | Initiation date: Oct 2025 --> Jun 2025 | Trial primary completion date: Feb 2026 --> Nov 2026
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    4d
    Single-cell RNA-seq reveals breast cancer heterogeneity and identifies TCP1 as a therapeutic target in breast cancer. (PubMed, PeerJ)
    Focusing on TCP1, a chaperonin subunit upregulated in high-risk tumors, we demonstrate that TCP1 knockdown in breast cancer cell lines substantially impairs cell migration (~50% reduction in wound closure) and invasion (P < 0.01). These findings reveal functionally distinct malignant cell states within breast cancer and identify TCP1 as a promising therapeutic target to disrupt aggressive, stem-like tumor cell programs, ultimately guiding more personalized treatment strategies.
    Journal • BRCA Biomarker
    |
    ER (Estrogen receptor) • BRCA1 (Breast cancer 1, early onset) • ERG (ETS Transcription Factor ERG) • KRT17 (Keratin 17) • NFKBIA (NFKB Inhibitor Alpha 2) • PDLIM4 (PDZ and LIM domain 4)
    |
    ER positive
    4d
    Individualized Breast Surveillance in a Young Hodgkin Lymphoma Survivor With High-Risk Features. (PubMed, Cureus)
    This case illustrates the importance of risk-stratified, multidisciplinary assessment of new breast findings in adolescent and young adult (AYA) cancer survivors. Individualized, radiation-sparing imaging strategies coupled with comprehensive survivorship follow-up enable early detection, genetic risk identification, and longitudinal care coordination for patients at dual risk from prior therapy and hereditary predisposition.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset)
    4d
    Fine-needle aspiration cytology of Hodgkin-like ALK-negative anaplastic large cell lymphoma: Cytomorphological clues and the diagnostic value of subtle background cell atypia. (PubMed, J Clin Exp Hematop)
    Careful assessment of nuclear morphology and cell distribution patterns can provide valuable diagnostic clues to prevent misdiagnosis. This rare cytological presentation offers critical educational insights for cytopathologists and underscores the diagnostic value of FNA cytology, particularly when integrated with immunophenotypic analysis and retrospective morphological review in evaluating morphologically challenging lymphoid malignancies.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PAX5 (Paired Box 5) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • GZMB (Granzyme B) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    ALK negative
    6d
    Nodal T-follicular helper cell lymphoma with hodgkin/reed-sternberg-like cells: Clinicopathologic and molecular characterization of 11 cases. (PubMed, Pathol Res Pract)
    AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    DNMT3A (DNA methyltransferase 1) • PD-1 (Programmed cell death 1) • TNFRSF8 (TNF Receptor Superfamily Member 8) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CREBBP (CREB binding protein) • PAX5 (Paired Box 5) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • RHOA (Ras homolog family member A) • MME (Membrane Metalloendopeptidase) • BRD4 (Bromodomain Containing 4)
    |
    TET2 mutation • TNFRSF8 positive • TNFRSF8 expression
    |
    CART-30
    8d
    Redefining the Spectrum of EBV-Positive Diffuse Large B-Cell Lymphoma and EBV-Positive Classic Hodgkin Lymphoma. (PubMed, Mod Pathol)
    Moreover, these groups were identified using surrogate immunohistochemical markers: EBNA2, PDL1, and IDO1. In conclusion, the molecular studies assessing tumor-host interaction enhances understanding of the EBV+ large B-cell lymphoma spectrum and benefits pathological diagnosis and clinical management.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    PD-L1 expression
    8d
    Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment (clinicaltrials.gov)
    P2, N=23, Not yet recruiting, City of Hope Medical Center
    New P2 trial
    |
    Keytruda (pembrolizumab) • gemcitabine • Adcetris (brentuximab vedotin) • dacarbazine
    9d
    Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy. (PubMed, J Hematop)
    A notable feature of the HRS-like cells in this case is the gain of markers associated with CHL, such as CD30 and CD15. This immunophenotypic shift highlights the concept of lymphoma plasticity, where the tumor cells evolve in response to selective pressures, such as CAR T cell therapy.
    Journal
    |
    TP53 (Tumor protein P53) • CD19 (CD19 Molecule) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1)
    |
    Chr t(11;14) • TP53 deletion
    9d
    Therapy-related Myeloid Neoplasms After Autologous Stem Cell Transplantation for Lymphoma: A Single-Center Experience. (PubMed, Blood Cell Ther)
    dexamethasone, ara-C, cisplatin (DHAP) was the most common salvage regimen (47.8%)...BCNU, etoposide, ara-C, melphalan (BEAM) was the most common conditioning regimen 91.9%...t-MN significantly contributes to NRM post-auto-HCT. Age at transplant is the primary risk factor, highlighting the need for vigilant monitoring and risk mitigation strategies.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    cisplatin • cytarabine • etoposide IV • dexamethasone • melphalan